Abstract

Mesenchymal Stem Cell (MSC) Transplantation in Patients with Amyotrophic Lateral Sclerosis (ALS): Is there a “Responder Population”?

Objective: To analyze the safety and clinical effect of stem cell therapy in ALS.

Methods: In phase I of the trial, ALS subjects have been intrathecally transplanted with autologous bone marrowderived mesenchymal stem cells (MSCs) using a surgical procedure.

Results: We present the results of a 6-month interim analysis of the ongoing study. Intrathecal administration of MSCs into ALS patients was feasible and safe. We showed a clinical benefit evident for the entire group of patients (n=25). The mean rate of ALSFRS-R score change (decrease) pre-transplant was 1.76 ± 1.36 points/period whereas the mean post-transplant rate was 1.06 ± 0.9 points/period (p=0.014). The key finding of our study is that there appears to be a group of patients, whom we call “responders” whose reaction to the treatment was different from the reaction of other patients we call “nonresponders”.

Conclusion: In our study the “responders” progressed faster prior to the treatment than “non-responders”. Hence, we hypothesize that the pre-treatment progression rate may play a role as a predictive factor and a criterion for selecting ALS patients for cell-based therapies.


Author(s):

Tomasz Siwek, Monika Barczewska, Łukasz Grabarczyk, Mariusz Sowa, Katarzyna Jezierska-Wozniak, Aleksandra Habich, Joanna Wojtkiewicz, Wanda Badowska and Wojciech Maksymowicz



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

Flyer image

Abstracted/Indexed in

  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor